These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 27973438)

  • 41. Pancreatic and gastrointestinal hormones in chronic pancreatitis.
    Stasiewicz J; Adler M; Delcourt A
    Hepatogastroenterology; 1980 Apr; 27(2):152-60. PubMed ID: 7011929
    [No Abstract]   [Full Text] [Related]  

  • 42. Regular exercise coupled to diet regimen accelerates reduction of hepatic steatosis and associated pathological conditions in nonalcoholic fatty liver disease.
    Oh S; Tanaka K; Tsujimoto T; So R; Shida T; Shoda J
    Metab Syndr Relat Disord; 2014 Jun; 12(5):290-8. PubMed ID: 24689911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
    Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
    World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.
    Wree A; Schlattjan M; Bechmann LP; Claudel T; Sowa JP; Stojakovic T; Scharnagl H; Köfeler H; Baba HA; Gerken G; Feldstein AE; Trauner M; Canbay A
    Metabolism; 2014 Dec; 63(12):1542-52. PubMed ID: 25267016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.
    Hannah WN; Harrison SA
    Clin Liver Dis; 2016 May; 20(2):339-50. PubMed ID: 27063273
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adzuki bean ameliorates hepatic lipogenesis and proinflammatory mediator expression in mice fed a high-cholesterol and high-fat diet to induce nonalcoholic fatty liver disease.
    Kim S; Hong J; Jeon R; Kim HS
    Nutr Res; 2016 Jan; 36(1):90-100. PubMed ID: 26773785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cholesterol is a significant risk factor for non-alcoholic steatohepatitis.
    Walenbergh SM; Shiri-Sverdlov R
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1343-6. PubMed ID: 26395315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammatory response in visceral fat tissue and liver is prenatally programmed: experimental research.
    Bezpalko L; Gavrilyuk O; Zayachkivska O
    J Physiol Pharmacol; 2015 Feb; 66(1):57-64. PubMed ID: 25716965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease.
    Cheng S; Wiklund P; Autio R; Borra R; Ojanen X; Xu L; Törmäkangas T; Alen M
    PLoS One; 2015; 10(10):e0138889. PubMed ID: 26439744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
    Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
    Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating homocysteine in nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Tsoukas MA
    Eur J Intern Med; 2015 Mar; 26(2):152-3. PubMed ID: 25676807
    [No Abstract]   [Full Text] [Related]  

  • 54. Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Margouta A; Mantzoros CS
    Endocrine; 2015 Jun; 49(2):560-2. PubMed ID: 25381603
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical aspects of gut hormones and neuropeptides.
    Bloom SR; Polak JM
    Br Med Bull; 1982 Sep; 38(3):233-8. PubMed ID: 6129021
    [No Abstract]   [Full Text] [Related]  

  • 56. Non-alcoholic fatty liver disease in children and adolescents.
    Penke M; Kiess W; Giorgis T
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1329-1330. PubMed ID: 27861140
    [No Abstract]   [Full Text] [Related]  

  • 57. Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease.
    Kim CW; Kim HY
    Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1330-1. PubMed ID: 26510544
    [No Abstract]   [Full Text] [Related]  

  • 58. Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease--authors' reply.
    Wong VW; Chan HL
    Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1331-2. PubMed ID: 26510545
    [No Abstract]   [Full Text] [Related]  

  • 59. Proper cut-off points to distinguish patients with NASH from non-NASH.
    Sertoglu E; Kayadibi H; Uyanik M
    Eur J Intern Med; 2015 Jan; 26(1):74. PubMed ID: 25468251
    [No Abstract]   [Full Text] [Related]  

  • 60. Liver-adipose tissue crosstalk in non-alcoholic fatty liver disease: The emerging role of remnant cholesterol.
    Liu Y; Chen M
    J Hepatol; 2024 Mar; 80(3):e111-e112. PubMed ID: 37380106
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.